SCHEMBL3490260

SCHEMBL3490260

CC1(C(=O)O)CCC[C@@]2(C)[C@H]1CC[C@@]13CC[C@H](CC[C@@H]12)C3

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F10 P00742 6/20 0.66
HSD11B1 P28845 2/20 0.62
PTPN1 P18031 3/20 0.62
PTPN2 P17706 1/20 0.57
CDC25B P30305 1/20 0.57
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
KMT2A Q03164 1/20 0.49
SELP P16109 1/20 0.47
CYP2C9 P11712 1/20 0.45
PAX8 Q06710 1/20 0.43
MMP2 P08253 1/20 0.42
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
RPA1 P27694 1/20 0.40
HIF1A Q16665 1/20 0.40
EPAS1 Q99814 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490256 1.00 F10 (0.66) F10HSD11B1PTPN1PTPN2CDC25B
SCHEMBL29626878 0.80 F10 (0.66) F10HSD11B1PTPN1PTPN2CDC25B
SCHEMBL22922196 0.80 F10 (0.66) F10HSD11B1PTPN1PTPN2CDC25B
SCHEMBL22922186 0.80 F10 (0.66) F10HSD11B1PTPN1PTPN2CDC25B
SCHEMBL30997030 0.80 PTPN1 (0.59) F10HSD11B1PTPN1PTPN2CDC25B
SCHEMBL29626875 0.80 PTPN1 (0.59) F10HSD11B1PTPN1PTPN2CDC25B
SCHEMBL2021012 0.80 PTPN1 (0.59) F10HSD11B1PTPN1PTPN2CDC25B
SCHEMBL2021014 0.80 PTPN1 (0.59) F10HSD11B1PTPN1PTPN2CDC25B
SCHEMBL3490073 0.79 HSD11B1 (0.65) F10HSD11B1PTPN1PTPN2CDC25B
SCHEMBL3490070 0.79 HSD11B1 (0.65) F10HSD11B1PTPN1PTPN2CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155769-B1 TISSUE DEGENERATION PROTECTION UNIV LEUVEN KATH (BE) 2012-06-27 EP claimed
US-20100099640-A1 TISSUE DEGENERATION PROTECTION GEUNS JOANNES 2010-04-22 US claimed
EP-2155769-A2 TISSUE DEGENERATION PROTECTION Katholieke Universiteit Leuven (BE) 2010-02-24 EP claimed
WO-2008134828-A2 TISSUE DEGENERATION PROTECTION KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2008-11-13 WO claimed
EP-2155769-B1 TISSUE DEGENERATION PROTECTION UNIV LEUVEN KATH (BE) 2012-06-27 EP disclosed
US-20100099640-A1 TISSUE DEGENERATION PROTECTION GEUNS JOANNES 2010-04-22 US disclosed
EP-2155769-A2 TISSUE DEGENERATION PROTECTION Katholieke Universiteit Leuven (BE) 2010-02-24 EP disclosed
WO-2008134828-A2 TISSUE DEGENERATION PROTECTION KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099640-A1 TISSUE DEGENERATION PROTECTION SORD, CASP3, TXNRD2 F10 551/4885HSD11B1 187/4885PTPN1 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.